Despite the results, Martin Holst Lange, Chief Scientific Officer and Executive Vice President of Research and Development at Novo Nordisk, said in the press release, We are proud to have conducted two well-controlled phase 3 trials in Alzheimers disease that meet the highest standards of research and rigorous methodology. Scientists like Sally Frautschy, a neuroscientist studying AD at the University of California, Los Angeles, agreed that the trial was well-designed to answer the question, and told DDN that Alzheimers involves clear deficits in insulin signaling, so GLP-1 receptor agonists were a logical target. However, Frautschy was not surprised by the results
doi: 10.1016/j.pnpbp.2018.12.015
Is high-dose vitamin C safe
Want to compare sleeve, bypass, SADI, balloon, and medication options in one program
Mounjaro (tirzepatide) gained FDA approval on May 13, 2022
Lifestyle Factors and Glutathione Besides consuming glutathione foods, making smart lifestyle choices is also essential